Investigational drug · Phase 3
PF-08046054
Also called: SGN-PDL1V
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "PF-08046054"
First trial start
2025
Sep 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-08046054", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Carcinoma
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Carcinoma
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-08046054" as an intervention, largest first.
Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
NCT05208762 · 714 participants (planned) · Start Oct 25, 2022 · Primary completion Jan 5, 2028
Drug: PF-08046054; pembrolizumab · For: Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of the Head and Neck; Esophageal Squamous Cell Carcinoma and 5 more
Sites: Birmingham, Alabama; Irvine, California; Orange, California · 62 sites in all
- A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07144280 · 680 participants (planned) · Start Sep 29, 2025 · Primary completion Mar 10, 2028
Drug: PF-08046054; Docetaxel monotherapy · For: Non-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Carcinoma
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 469 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 104 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.